Research Interests
Biomarkers of prostate cancer
Quantitative imaging of genitorurinary cancers
Surgical innovation
Quantitative imaging of genitorurinary cancers
Surgical innovation
Selected Grants
NWU22-12-01 A PHASE 2 PLACEBO-CONTROLLED TRIAL OF UROLITHIN A SUPPLEMENTATION IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
Clinical TrialPrincipal Investigator · Awarded by Northwestern University · 2024 - 2031Phase 1, open label, dose escalation and dose expansion study to eval the safety, tolerability, pharmacokinetics and antitumor activity of PF-08052667 as a single agent and in comb therapy in participants 18 years of age and older with bladder cancer
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2026 - 2031TYRA-300
Clinical TrialPrincipal Investigator · Awarded by Tyra Biosciences, Inc. · 2026 - 2031NWU22-12-01 A PHASE 2 PLACEBO-CONTROLLED TRIAL OF UROLITHIN A SUPPLEMENTATION IN MEN WITH PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY
ResearchPrincipal Investigator · Awarded by Northwestern University · 2024 - 2030Droplet Surgical drain for detection of MRD Pro00115296
Clinical TrialPrincipal Investigator · Awarded by Droplet Biosciences · 2024 - 2029Medtronic Expand URO - Pro00108661
Clinical TrialPrincipal Investigator · Awarded by Medtronic, Inc. · 2021 - 2027Bladder EpiCheck for detection of recurrent Urothelial Carcinoma
ResearchPrincipal Investigator · Awarded by Nucleix Ltd. · 2026 - 2027A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer
Clinical TrialPrincipal Investigator · Awarded by Surge Therapeutics · 2024 - 2026B042843 Phase III Study of Atezolozumab vs Placebo in Patients with High Risk Muscle Invasive Bladder Cancer who are CTDNA positive following Cystectomy
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2023 - 2025External Relationships
- Droplet
- Medtronic
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.